CR Bard’s Lutonix wins Medicare reimbursement add-on

C.R. Bard (NYSE:BCR) said today that angioplasty treatments with its Lutonix drug-coated balloon will now be eligible for add-on payments through the Centers for Medicare and Medicaid Services under Medicare’s hospital impatient prospective payment systems.

The add-on payment, with a maximum of $1,036, will help cover additional costs for treating patients with the Lutonix during inpatient settings and is slated to go into effect October 1, C.R. Bard said.

“After providing reimbursement in the outpatient setting earlier this year, CMS has now provided additional reimbursement for the Lutonix DCB in the inpatient setting, which demonstrates the benefit to patients from this breakthrough technology,” CEO Timothy Ring said in a prepared statement.

The Lutonix was the first DCB approved by the FDA, C.R. Bard said, and is used for the treatment of peripheral artery disease in the femoropopliteal arteries.

C.R. Bard posted a classic beat-&-raise 2nd quarter last week, topping both sales and earnings expectations and raising its outlook for the rest of the year.

The post CR Bard’s Lutonix wins Medicare reimbursement add-on appeared first on MassDevice.

from MassDevice http://ift.tt/1N4oX4k